Literature DB >> 19406621

BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis.

Kunihiro Kawashima1, Masashi Ikeda, Taro Kishi, Tsuyoshi Kitajima, Yoshio Yamanouchi, Yoko Kinoshita, Tomo Okochi, Branko Aleksic, Makoto Tomita, Takeya Okada, Hiroshi Kunugi, Toshiya Inada, Norio Ozaki, Nakao Iwata.   

Abstract

A variety of evidence suggests brain-derived neurotrophic factor (BDNF) as a candidate gene for schizophrenia, and several genetic studies have shown a significant association between the disease and certain SNPs within BDNF (specifically, Val66Met and C270T). According to a recent study, the functional microsatellite marker BDNF-LCPR (BDNF-linked complex polymorphic region), which affects the expression level of BDNF, is associated with bipolar disorder. The goals of our current study were to 1) evaluate the quality of HapMap-based linkage disequilibrium (LD) tagging of BDNF-LCPR, 2) examine whether these tagging SNPs are associated with schizophrenia in a Japanese population, and 3) conduct a meta-analysis of the two most extensively studied polymorphisms: Val66Met and C270T. We genotyped eight tagging SNPs, including Val66Met and C270T. Our LD evaluation showed that BDNF-LCPR could be represented by these tagging SNPs in controls (with 73.5% allelic coverage). However, the functional A1 allele was not captured due to its low minor allele frequency (2.2%). In a case-control study (1117 schizophrenics and 1102 controls), no association was found in single-marker or multimarker analysis. Moreover, in a meta-analysis, the Val66Met polymorphism was not associated with schizophrenia, whereas C270T showed a trend for association in a fixed model (p=0.036), but not in a random model (p=0.053). From these findings, we conclude that if BDNF is indeed associated with schizophrenia, the A1 allele in BDNF-LCPR would be the most promising candidate. Further LD evaluation, as well as an association study in which BDNF-LCPR is genotyped directly, would be required for a more conclusive result.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406621     DOI: 10.1016/j.schres.2009.03.040

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

Review 1.  The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.

Authors:  M Notaras; R Hill; M van den Buuse
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

Review 2.  Genomics and pharmacogenomics of schizophrenia.

Authors:  Ramón Cacabelos; Rocío Martínez-Bouza
Journal:  CNS Neurosci Ther       Date:  2010-08-16       Impact factor: 5.243

3.  Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Maja Zivkovic; Marina Sagud; Suzana Uzun; Alma Mihaljevic-Peles; Oliver Kozumplik; Dorotea Muck-Seler; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2014-03-05       Impact factor: 4.530

Review 4.  Myelin, copper, and the cuprizone model of schizophrenia.

Authors:  Nicole R Herring; Christine Konradi
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

5.  BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory.

Authors:  R Nieto; M Kukuljan; H Silva
Journal:  Front Psychiatry       Date:  2013-06-17       Impact factor: 4.157

6.  A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia.

Authors:  Milawaty Nurjono; Jimmy Lee; Siow-Ann Chong
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

7.  Modulatory effects of brain-derived neurotrophic factor Val66Met polymorphism on prefrontal regions in major depressive disorder.

Authors:  Rebecca MacGregor Legge; Shahbaz Sendi; James H Cole; Sarah Cohen-Woods; Sergi G Costafreda; Andrew Simmons; Anne E Farmer; Katherine J Aitchison; Peter McGuffin; Cynthia H Y Fu
Journal:  Br J Psychiatry       Date:  2015-03-05       Impact factor: 9.319

8.  Association of serum brain derived neurotropic factor with duration of drug-naive period and positive-negative symptom scores in drug naive schizophrenia.

Authors:  Abdurrahim Bakirhan; Safak Yalcin Sahiner; Ismail Volkan Sahiner; Yasir Safak; Erol Goka
Journal:  PLoS One       Date:  2017-12-29       Impact factor: 3.240

Review 9.  Theranostic Biomarkers for Schizophrenia.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Dubravka Svob Strac; Suzana Uzun; Oliver Kozumplik; Nela Pivac
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

Review 10.  Critical Issues in BDNF Val66Met Genetic Studies of Neuropsychiatric Disorders.

Authors:  Shih-Jen Tsai
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.